[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.178.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 346
Citations 0
Comment & Response
September 2014

Progression to Hepatitis and Fibrosis Secondary to Lomitapide Use—Reply

Author Affiliations
  • 1Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts
  • 2Channing Division of Network Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
  • 3Harvard Medical School, Boston, Massachusetts
  • 4Harvard Vanguard Medical Associates, Boston, Massachusetts
  • 5Robarts Research Institute, London, Ontario, Canada
JAMA Intern Med. 2014;174(9):1522-1523. doi:10.1001/jamainternmed.2014.1528

In Reply We appreciate the opportunity to comment on the points raised by Miyares. First, we emphasize that use of lomitapide for any type of hyperlipidemia requires careful monitoring for hepatoxicity. In the case of familial chylomicronemia that we reported,1 changes in enzymes and biopsy specimens associated with hepatoxicity began to occur after about 9 years of use and became moderate to severe after 13 years. No other approved effective treatments could have been used, and lomitapide was made available under compassionate use. Currently, the patient is being followed up closely by a hepatologist and her clinical team.

First Page Preview View Large
First page PDF preview
First page PDF preview
×